MB and adenocarcinoma: Our study did not show differences between ICI-responsive MC38 adenocarcinomas (“hot tumors”) and ICI-resistant B16F10 melanomas (“cold tumors”) at baseline by 89Zr-mCD4-Mb immunoPET.